---
title: "INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295528829.md"
description: "Intensity Therapeutics reported a Q2 2026 net loss of $3.0M and diluted EPS of $(1.11), widening from the prior year's $2.5M loss. The company remains pre-revenue. Clinically, it initiated Phase 3 INVINCIBLE-3 and Phase 2 INVINCIBLE-4 trials, with FDA agreement on CMC plans for Phase 3 and NDA. However, funding constraints have paused broader site activations, limiting U.S. resumption pending additional capital."
datetime: "2026-08-11T11:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295528829.md)
  - [en](https://longbridge.com/en/news/295528829.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295528829.md)
generator: "portal-rs"
---

# INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary

INTENSITY THERAPEUTICS, INC. reported a consolidated net loss of $(3.0M) for the second quarter of 2026, compared with a $(2.5M) loss in the year-ago quarter; diluted loss per share was $(1.11) versus $(3.36) in Q2 2025. The company remains pre-revenue with no product or licensing revenue recognized for the quarter.

**Financial Highlights**

-   Revenue: Not reported for Q2 2026 (no product or licensing revenue; company remains pre-revenue).
-   Net income: $(3.0M) for Q2 2026, compared with $(2.5M) in Q2 2025; deterioration of $0.47M year-over-year.
-   Diluted EPS: $(1.11) for Q2 2026, compared with $(3.36) in Q2 2025.

**Business Highlights**

-   Clinical program progress: Completed Phase 1/2 IT-01 and Phase 2 INVINCIBLE-2; initiated Phase 3 INVINCIBLE-3 and Phase 2 INVINCIBLE-4 with periods of paused and resumed enrollment.
-   Operations and manufacturing: Developed Phase 3 analytical methods and manufactured multiple large-scale GMP batches of INT230-6.
-   Regulatory engagement: FDA agreed on the CMC plan for Phase 3 and an NDA; INVINCIBLE-3 received authorization from the FDA, Health Canada, EMA and TGA.
-   Trial outcomes and biomarkers: INVINCIBLE-2 showed high tumor necrosis and immune activation; early INVINCIBLE-4 data indicated higher pathological complete response (pCR) rates and fewer grade 3 adverse events in the treatment arm.
-   Funding and enrollment impact: Funding constraints paused broader site activations, with limited U.S. resumption planned pending incremental capital.

Original SEC Filing: INTENSITY THERAPEUTICS, INC. \[ INTS \] - 10-Q - Aug. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [INTS.US](https://longbridge.com/en/quote/INTS.US.md)

## Related News & Research

- [Sherwin-Williams announces Q3 2026 dividend of R$ 0.28 per unit](https://longbridge.com/en/news/299050724.md)
- [ADM announces Q3 2026 dividend of R$ 0.22 per unit](https://longbridge.com/en/news/298917252.md)
- [Monolithic Power Systems declares Q3 2026 dividend of R$ 0.12 per unit](https://longbridge.com/en/news/298939350.md)
- [Prudential Financial announces R$ 2.41 per unit dividend for Q3 2026 BDRs](https://longbridge.com/en/news/298940810.md)
- [Cembre announces deposit of H1 2026 interim report](https://longbridge.com/en/news/298719151.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**